2024’s Biggest Marketing Stories
Point of care messaging and AI resulted in more targeted campaigns over the past year.
Stock.adobe.com
Emerging Trends at the Intersection of AI & Marketing
In this Pharmaceutical Executive video interview, Kaveh Vahdat, Founder and President of RiseOpp, talks about what's coming marketing with the use of AI.
From Identity to Margin: Securing Audience Measurement in Pharma Marketing
The industry must find a way to balance consumer privacy and a return on investment in pharma marketing.
Point of care messaging offers unique advantages in pharmaceutical marketing and should be a high priority in brand strategy discussions.
Thursday Night DTC Marketing: Q&A with Dan Switzer
Daiichi Sankyo’s head of US oncology business discusses the company’s first DTC television campaign for Enhertu.
Bringing Marketing to a New Audience: Q&A with Jeremy Truxal
Truxal discusses Exact Science’s first Spanish language TV commercial and campaign for Cologuard.
Using AI and Advanced Analytics Tools to Optimize Marketing Strategies
In this part of her video interview, Amanda Powers-Han, Chief Marketing Officer, Greater Than One and Pharmaceutical Executive Advisory Board Member discusses how CMOs can leverage artificial intelligence and other advanced analytics tools to extract meaningful insights and optimize marketing strategies.
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves AbbVie’s Rinvoq as First Oral JAK Inhibitor for Giant Cell Arteritis
April 30th 2025AbbVie secures FDA approval for Rinvoq as the first oral Janus kinase inhibitor indicated for giant cell arteritis, expanding its immunology portfolio and signaling strategic growth opportunities in underserved autoimmune markets.
